Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. (Nasdaq: VANI) is a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants based on its NanoPortal™ platform, along with neuromodulation devices through its Cortigent subsidiary. The VANI news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Vivani’s clinical programs, financings, and corporate actions evolve over time.
Recent Vivani news has highlighted progress with NPM-139, a semaglutide GLP-1 implant program for chronic weight management, including plans for a Phase 1 clinical study and preparations for a potential Phase 2 dose-ranging trial, subject to regulatory clearance and supportive data. The company has also reported results from the LIBERATE-1 Phase 1 study of its exenatide implant NPM-115, which it describes as the first-in-human application of the NanoPortal technology, as well as preclinical data suggesting sustained weight loss from a single NPM-139 implant in ongoing studies.
In addition to R&D updates, Vivani’s news flow includes announcements of equity financings, such as private placements and a registered direct offering of common stock, with stated use of proceeds for research, clinical development, working capital and general corporate purposes. The company also issues news about its proposed spin-off of Cortigent, Inc., which develops brain implant devices like the Orion® visual cortical prosthesis system and a stroke recovery neurostimulation platform.
Investors and followers of VANI can use this page to monitor clinical milestones, capital-raising transactions, conference presentations, and key steps in the Cortigent spin-off process, all drawn from Vivani’s own press releases and related regulatory communications.
Vivani Medical, Inc. (NASDAQ: VANI) has announced its trading debut on The Nasdaq Capital Market today following its merger with Nano Precision Medical, Inc. The company holds approximately $55 million in cash, aimed at advancing its product portfolio which includes the NPM-119 (exenatide implant) for Type 2 diabetes. Vivani’s focus is on developing drug and device implants for chronic diseases and visual prostheses for blindness. CEO Adam Mendelsohn expressed optimism about the future of the company and its technologies, particularly the NanoPortal implant technology.
Second Sight Medical Products, Inc. has successfully merged with Nano Precision Medical, Inc., now rebranded as Vivani Medical, Inc., trading under the ticker VANI on Nasdaq. Following the merger, Vivani has approximately $55 million to develop products, including the NPM-119 implant for diabetes treatment and the Orion visual prosthesis for blind patients. The leadership team, led by NPM’s CEO Dr. Adam Mendelsohn, aims to tackle medication non-adherence and advance innovative therapies.